Retatrutide
In stockLY3437943Retatrutide (LY3437943) is a 39-residue lipidated peptide with a C20 fatty diacid chain that targets the GIP, GLP-1 and glucagon receptors. It is an investigational compound that researchers study for receptor pharmacology and analytical detection.
Supplied as a single-chamber lyophilized vial with a colour-coded cap (Weight Regulation).
Research literature, not dosing or treatment instructions.
- A 2026 analytical paper describes retatrutide as a long-acting triple incretin receptor agonist that targets GLP-1R, GIPR and the glucagon receptor, and reports its detection in human plasma and urine by LC-HRMS. (PMID 42745421)
- A 2026 paper compared semaglutide, tirzepatide and retatrutide in human kidney cells and in mouse models of renal fibrosis and ageing. (PMID 42630988)
Add the solvent slowly along the vial wall; swirl gently, never shake. Allow to dissolve fully. Six-step guide with photos →
Concentration calculator only. Enter the mass being calculated; blend components are not added automatically. Products are for in-vitro research.
Refer to the product label and supplier documentation for storage conditions. Lot-specific storage and expiry information is not available here.
Each certificate is published with its lot number.
Questions about Retatrutide
How much published research is there on Retatrutide?
The research library's PubMed search for Retatrutide returned 197 records on 5 October 2026, 117 of them reviews. The library lists 2 studies chosen for what they measured. ClinicalTrials.gov lists 33 registered studies naming Retatrutide, 32 of them sponsored by Eli Lilly and Company (checked 5 October 2026).
Is Retatrutide an approved medicine?
No centrally authorised medicine containing Retatrutide is listed in the EMA medicines database (checked 5 October 2026), and the research material we supply is not a medicine. It is supplied for in-vitro laboratory research only, not for human or veterinary use.
What does LY3437943 refer to?
LY3437943 is the development code of retatrutide, a 39-residue lipidated peptide that targets the GIP, GLP-1 and glucagon receptors.
Why does the literature list show so few papers for retatrutide?
Clinical trial papers state clinical outcomes in their titles and endpoints, so the research library lists only chemistry, analytical and pharmacology papers: a 2026 analytical paper on detection by LC-HRMS (PMID 42745421) and a 2026 comparison in human kidney cells and mouse models (PMID 42630988).
How does Retatrutide differ from Tirzepatide?
Tirzepatide acts at the GIP and GLP-1 receptors. Retatrutide adds the glucagon receptor as a third target. Both are 39-residue lipidated peptides. Tirzepatide is an authorised medicine in the US, EU and UK; retatrutide is investigational.
How is the identity of Retatrutide confirmed on a certificate?
A research-grade certificate of analysis typically reports identity by mass spectrometry and purity by HPLC. The mass result is read against the average molecular weight of 4731.4 Da listed on this page. The research library's guide to reading a certificate explains each field.
Is this product for human use?
No. Peptency products are supplied for in-vitro research only. Not for human or veterinary use, not for diagnosis or therapy.
Where can I find shipping information?
Current shipping rates and delivery information are on the Shipping & payment page, and the rates that apply to your order are shown at checkout.
Often studied with
For research use only. Not for human or veterinary use.
What is Retatrutide?
Retatrutide (LY3437943) is a 39-residue lipidated peptide with a C20 fatty diacid chain that targets the GIP, GLP-1 and glucagon receptors. It is an investigational compound with no marketing authorisation recorded in the databases checked. We supply Retatrutide as a lyophilized vial for in-vitro laboratory research only.
What are the chemical identifiers of Retatrutide?
Retatrutide has the molecular formula C221H342N46O68, an average molecular weight of 4731.4 Da and CAS number 2381089-83-2.
Chemistry checked against PubChem (CID 171390338), 5 October 2026; full chemistry record in the research library.
What does published research on Retatrutide cover?
A PubMed search for Retatrutide returned 197 records on 5 October 2026, 117 of them reviews. Our research library lists 2 of these studies, chosen for what they measured.
- A 2026 analytical paper describes retatrutide as a long-acting triple incretin receptor agonist that targets GLP-1R, GIPR and the glucagon receptor, and reports its detection in human plasma and urine by LC-HRMS. (Carneiro et al., Rapid Commun Mass Spectrom, 2026; PMID 42745421)
- A 2026 paper compared semaglutide, tirzepatide and retatrutide in human kidney cells and in mouse models of renal fibrosis and ageing. (Ding et al., iScience, 2026; PMID 42630988)
Mechanism, every cited study and the regulator records are on the Retatrutide page of the research library. Papers are listed by what they measured, not as evidence of any use.
How is Retatrutide supplied and stored?
Retatrutide is supplied as a lyophilized (freeze-dried) powder in a sealed vial, for in-vitro laboratory research only. Our stated storage condition for the sealed lyophilized vial is 2 to 8 °C. The label and the lot certificate carry the lot-specific storage condition and expiry date.
What is the regulatory status of Retatrutide?
The EMA medicines database (checked 5 October 2026) lists no centrally authorised medicine naming Retatrutide as an active substance. National authorisations are not in that dataset.
No SmPC, PIL or PAR document in MHRA Products matches the exact name (checked 5 October 2026).
A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Which related research pages and compounds are listed?
- Retatrutide: chemistry, literature and regulatory status
- Retatrutide compared with Tirzepatide
- Incretin and glucagon receptors
- How to read a certificate of analysis
Related compounds in the catalog: